surged sharply, breaking out of a multi-week consolidation zone with heavy volumes (~1.6M). The stock formed a long bullish candle, indicating strong institutional buying interest. RSI near 70 shows healthy momentum without deep overbought pressure. Key support sits near ₹3,650; immediate resistance is seen around ₹3,950–₹4,000. Fundamental View: Torrent Pharma’s Q2FY26 results exceeded street estimates with PAT up 23% YoY and margin expansion to 32%. Growth was driven by robust India business (+14%) and steady U.S. sales. The company’s focus on chronic therapies, cost optimization, and integration of acquired brands continues to pay off. Its strong cash flow, declining debt, and improving export outlook make it a steady compounder in pharma. Analyst Rating: Brokerages remain Positive/BUY, citing leadership in branded generics and stable margins. Target: ₹4,050 (≈6% upside) | Stop-loss: ₹3,650.

#FundamentalViews#TechnicalViews#StockInNews

651 likes·53 comments